Clinical Trial Update: Treatment of Alzheimer's Disease With CX516 (Ampalex) [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial of CX516 (Ampalex) in Alzheimer's disease (dementia).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Ampalex (CX516)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Alzheimer's Disease, Dementia | Phase 2 | Status: COMPLETED